Study guide

2.4 Alpha and Beta Thalassemias

ASCP Hematology Technologist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Hematopoiesis & Cellular Physiology

1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors 1.2 Erythrocyte Physiology, Metabolism & Destruction Pathways 1.3 Leukocyte Kinetics, Morphology & Phagocytic Function 1.4 Platelet Physiology, Ultrastructure & Thrombopoiesis

2 Chapter 2: Erythrocyte Disorders & Non-Hemolytic Anemias

2.1 Iron Metabolism & Iron Deficiency Anemia 2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity 2.3 Hemoglobinopathies & Qualitative Globin Chain Defects 2.4 Alpha and Beta Thalassemias 2.5 Megaloblastic, Macrocytic & Hypoproliferative Anemias

3 Chapter 3: Hemolytic Anemias & Erythrocytosis

3.1 Intrinsic Hemolytic Anemias: Membrane & Metabolic Defects 3.2 Immune-Mediated Hemolytic Anemias & Paroxysmal Nocturnal Hemoglobinuria 3.3 Non-Immune Extrinsic Hemolytic Anemias & Microangiopathies 3.4 Polycythemia & Erythrocytosis Classification

4 Chapter 4: Benign Leukocyte Alterations, Acute Leukemias & Bone Marrow Evaluation

4.1 Quantitative Leukocyte Alterations, Toxic Change & Leukemoid Reaction 4.2 Inherited Leukocyte Anomalies, Reactive Lymphocytosis & Storage Disorders 4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms 4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms 4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment

5 Chapter 5: Chronic Myeloid Neoplasms, MDS & Mature Lymphoid Neoplasms

5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes 5.2 Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF) 5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas 5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders 5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies

6 Chapter 6: Hemostasis: Primary, Secondary & Fibrinolytic Systems

6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders 6.2 Quantitative Platelet Disorders & Immune Thrombocytopenias 6.3 The Coagulation Cascade & Cell-Based Hemostatic Model 6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia

7 Chapter 7: Factor Deficiencies, Coagulation Testing & Anticoagulation

7.1 Hereditary Coagulation Factor Deficiencies & von Willebrand Disease 7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC 7.3 Routine and Specialized Coagulation Testing & Mixing Study Interpretation 7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies 7.5 Viscoelastic Testing, Heparin Neutralization & Chromogenic Assays

8 Chapter 8: Hematology Laboratory Testing & Advanced Diagnostics

8.1 Automated Hematology Analyzers, Interference Flags & Manual Methods 8.2 Cytochemical Staining, Flow Cytometry & Molecular Diagnostics 8.3 Erythrocyte Sedimentation Rate, Hemolytic Indicators & Special Erythrocyte Studies 8.4 Cerebrospinal Fluid Analysis, Cell Counts & Cytology 8.5 Serous Effusions & Synovial Fluid Analysis

9 Chapter 9: Laboratory Operations, Quality Assessment & Safety

9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality 9.2 Quality Control Statistics, Levey-Jennings Charts & Westgard Multirules 9.3 Laboratory Mathematics: Dilutions, Concentration, Molarity & Standard Curves 9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing 9.5 Regulatory Framework, Proficiency Testing & Competency Assessment 9.6 Laboratory Safety: Bloodborne Pathogens, Personal Protective Equipment & Chemical Hygiene 9.7 Emergency Response, Spill Management & Specimen Packaging and Transport 9.8 Hematology Instrumentation: Microscopy, Counters, Analyzers & Centrifuges

2.4 Alpha and Beta Thalassemias

Key Takeaways Explain This Topic AI

Thalassemias are quantitative globin chain synthesis disorders caused by gene deletions (predominantly alpha) or point mutations (predominantly beta), causing chain imbalance and ineffective erythropoiesis.

Alpha thalassemia involves 4 alleles on chromosome 16: 1 deletion = silent carrier; 2 deletions = minor/trait (trans in Africa, cis in SE Asia); 3 deletions = Hb H disease (beta-4 tetramers, golf ball inclusions); 4 deletions = Hb Barts hydrops fetalis (gamma-4 tetramers, fatal in utero).

Beta thalassemia minor/trait presents with mild microcytic anemia, striking microcytosis (MCV 58–70 fL) with high RBC count (>5.0 x 10^12/L), Mentzer Index < 13, and diagnostic elevation of Hb A2 (3.5%–7.0%).

Beta thalassemia major (Cooley Anemia) causes severe transfusion-dependent anemia, massive ineffective erythropoiesis, frontal bossing, severe target cells, nucleated RBCs, and >90% Hb F.

The Kleihauer-Betke acid elution test differentiates fetal from maternal RBCs: adult Hb A elutes at pH 3.2 leaving ghost cells, while acid-resistant Hb F remains intact and stains dark pink.

Last updated: August 2026

Alpha and Beta Thalassemias

Thalassemias represent a diverse group of hereditary microcytic, hemolytic anemias caused by quantitative defects in globin chain synthesis. Unlike qualitative hemoglobinopathies (such as Hb S or Hb C), where structurally abnormal globin chains are synthesized at normal rates, thalassemias feature structurally normal globin chains produced at significantly reduced rates or completely absent .

Pathophysiologic Principle: Unpaired Globin Chain Precipitation

The fundamental pathology common to all thalassemias is globin chain synthesis imbalance . When synthesis of one globin chain is diminished, the unaffected partner globin chains accumulate in excessive, unmatched quantities: ┌─────────────────────────────────────────┐

  • │ Diminished Synthesis of One Chain │
  • │ (Alpha or Beta Globin Gene) │
  • └────────────────────┬────────────────────┘
  • │
  • ▼
  • ┌─────────────────────────────────────────┐
  • │ Accumulation of Excess Unpaired Chains │
  • └────────────────────┬────────────────────┘
  • │
  • ┌────────────────────────────────┴────────────────────────────────┐
  • ▼ ▼
  • [In Beta Thalassemia: Free Alpha Monomers] [In Alpha Thalassemia: Free Beta / Gamma Tetramers]
  • Highly insoluble, precipitate in erythroblasts • Form soluble tetramers (Hb H = β₄, Hb Barts = γ₄)
  • Severe mechanical membrane damage • Precipitate in mature erythrocytes as cells age
  • Apoptosis in marrow (Ineffective Erythropoiesis) • Chronic extravascular hemolysis & splenomegaly

Ineffective Erythropoiesis : In β \beta β -thalassemia, free α \alpha α -globin chains cannot form stable tetramers. Free α \alpha α -monomers precipitate inside developing bone marrow normoblasts, forming toxic inclusions that oxidize membrane lipids and proteins, triggering widespread apoptosis of erythroblasts before they can exit the marrow.

Extravascular Hemolysis : Erythrocytes that survive marrow maturation contain rigid inclusions. As they transit the splenic cords of Billroth, splenic macrophages recognize membrane damage and ingest the abnormal cells, causing chronic extravascular hemolysis.

Marrow Expansion & Skeletal Deformities : Severe anemia triggers massive compensatory secretion of erythropoietin, driving intense erythroid marrow expansion (up to 20–30 times normal). This causes bone cortex thinning, pathologic fractures, maxillary hyperplasia, frontal bossing, and classic "hair-on-end" (crew-cut) radiographic appearances on skull X-rays.

Alpha Thalassemias

Alpha thalassemia is governed by four functional α \alpha α -globin gene alleles (two identical tandem genes, α 2 \alpha_2 α 2 ​ and α 1 \alpha_1 α 1 ​ , on each chromosome 16: designated α α / α α \alpha\alpha/\alpha\alpha αα / αα ). Unlike β \beta β -thalassemia, which is predominantly caused by point mutations, α \alpha α -thalassemia is caused in >90% of cases by large gene deletions mediated by non-homologous crossing over during meiosis. Chromosome 16 Configuration: [ α2 │ α1 ] / [ α2 │ α1 ] (Normal: 4 functional genes)

  • 1 Deletion (-α/αα) : Silent Carrier ────────► Normal CBC / Borderline MCV
  • 2 Deletions (-α/-α) : Alpha Thal Minor (Trans) ──► Microcytosis, High RBC, Normal Electrophoresis
  • (--/αα) : Alpha Thal Minor (Cis) ──► High Risk of Hydrops in Offspring
  • 3 Deletions (--/-α) : Hemoglobin H Disease ───► β₄ Tetramers, Golf Ball Inclusions, Fast Band
  • 4 Deletions (--/--) : Hb Barts Hydrops Fetalis ► γ₄ Tetramers, Lethal in Utero
  • The Four Alpha Thalassemia Syndromes

Silent Carrier (One Gene Deletion: − α / α α -\alpha/\alpha\alpha − α / αα ) :

Three functional α \alpha α -genes maintain near-normal globin output.

Asymptomatic with normal complete blood count indices or borderline-low MCV (78–82 fL).

Hemoglobin electrophoresis in adults is completely normal (at birth, cord blood contains trace Hb Barts 1–2% ).

Alpha Thalassemia Trait / Minor (Two Gene Deletions) :

Trans Deletion ( − α / − α -\alpha/-\alpha − α / − α ) : One α \alpha α -gene deleted on each chromosome 16. Highly prevalent in African populations ; carriers can never produce an offspring with zero α \alpha α -genes ( − − / − − --/-- − − / − − ).

Cis Deletion ( − − / α α --/\alpha\alpha − − / αα ) : Both α \alpha α -genes deleted on the same chromosome 16. Highly prevalent in Southeast Asian and Mediterranean populations . Couples who are both cis carriers have a 25% risk of having a fetus with fatal Hb Barts Hydrops Fetalis ( − − / − − --/-- − − / − − ).

Clinical/Lab Findings : Mild microcytic hypochromic anemia (Hb 10–12 g/dL, MCV 65–75 fL) with a disproportionately elevated RBC count ( > 5.0 to 5.5 × 10 12 /L >5.0\text{ to }5.5\times 10^{12}\text{/L} > 5.0 to 5.5 × 1 0 12 /L ) . Routine adult hemoglobin electrophoresis is completely normal (Hb A >95%, Hb A 2 A_2 A 2 ​ 1.5–3.5%, Hb F <1%) because the remaining two genes produce balanced chains.

Hemoglobin H Disease (Three Gene Deletions: − − / − α --/-\alpha − − / − α ) :

Severe deficiency of α \alpha α -chain synthesis. Excess unmatched β \beta β -chains aggregate into soluble tetramers of four beta chains ( β 4 \beta_4 β 4 ​ tetramers = Hemoglobin H ).

Clinical Findings : Chronic moderate-to-severe hemolytic anemia (Hb 7–10 g/dL), splenomegaly, jaundice, and microcytosis (MCV 55–65 fL).

Supravital Incubation : When whole blood is incubated with Brilliant Cresyl Blue (BCB) or New Methylene Blue, redox dye action induces oxidative precipitation of Hb H, producing multiple fine, greenish-blue, evenly dispersed granules throughout erythrocytes, resembling a "golf ball" or "pitted raspberry" .

Electrophoresis : Fast-migrating anodal band at alkaline pH representing Hb H (5–30%) .

Hemoglobin Barts Hydrops Fetalis (Four Gene Deletions: − − / − − --/-- − − / − − ) :

Complete absence of α \alpha α -globin chain synthesis. In fetal life, excess unmatched γ \gamma γ -chains aggregate into tetramers of four gamma chains ( γ 4 \gamma_4 γ 4 ​ tetramers = Hemoglobin Barts ).

Pathophysiology : Hb Barts has an extremely high oxygen affinity ( P 50 ∼ 12 mmHg P_{50} \sim 12\text{ mmHg} P 50 ​ ∼ 12 mmHg compared to normal ∼ 27 mmHg \sim 27\text{ mmHg} ∼ 27 mmHg ) and cannot release oxygen to fetal tissues . This causes catastrophic intrauterine tissue hypoxia, massive hepatosplenomegaly, severe generalized edema (anasarca/hydrops fetalis), high-output cardiac failure, and intrauterine demise or death within minutes of birth.

Electrophoresis : 80–90% Hb Barts, absence of Hb A, Hb A 2 A_2 A 2 ​ , and Hb F, with small amounts of embryonic Hemoglobin Portland ( ζ 2 γ 2 \zeta_2\gamma_2 ζ 2 ​ γ 2 ​ ) .

Beta Thalassemias

Beta thalassemia is governed by two β \beta β -globin gene alleles (one gene on each chromosome 11: designated β / β \beta/\beta β / β ). In contrast to α \alpha α -thalassemia, β \beta β -thalassemia is caused in >95% of cases by point mutations affecting transcription promoters, RNA splicing junctions, or nonsense/frameshift mutations:

β 0 \beta^0 β 0 Allele : Complete absence of β \beta β -globin chain production.

β + \beta^+ β + Allele : Markedly reduced (10–50% of normal) β \beta β -globin chain production.

1. Beta Thalassemia Minor / Trait (Heterozygous: β + / β \beta^+/\beta β + / β or β 0 / β \beta^0/\beta β 0 / β )

Beta Thalassemia Minor is a common, clinically mild microcytic state that must be accurately differentiated from Iron Deficiency Anemia:

CBC Profile : Mild microcytic hypochromic anemia (Hb 10–13 g/dL), marked microcytosis ( MCV 58–70 fL ), and a strikingly elevated red blood cell count ( > 5.0 to 6.5 × 10 12 /L >5.0\text{ to }6.5\times 10^{12}\text{/L} > 5.0 to 6.5 × 1 0 12 /L ) with a normal RDW (11.5–14.5%).

Mentzer Index : Diagnostic mathematical ratio: Mentzer Index = MCV (fL) RBC Count ( 10 12 / L ) \text{Mentzer Index} = \frac{\text{MCV (fL)}}{\text{RBC Count } (10^{12}/\text{L})} Mentzer Index = RBC Count ( 1 0 12 / L ) MCV (fL) ​

Mentzer Index < 13 : Strongly indicates Thalassemia Trait (the marrow generates many small microcytes).

Mentzer Index > 13 : Strongly indicates Iron Deficiency Anemia (iron deficiency restricts total cell production, lowering RBC count relative to MCV).

Definitive Diagnostic Hallmark : Quantification by HPLC or microcolumn chromatography demonstrates an elevated Hemoglobin A 2 A_2 A 2 ​ (3.5% to 7.0%) (normal is 1.5–3.5%) and slightly elevated Hemoglobin F (1.0% to 3.0%) .

2. Beta Thalassemia Intermedia (Homozygous/Compound Heterozygous: β + / β + \beta^+/\beta^+ β + / β + or β 0 / β + \beta^0/\beta^+ β 0 / β + )

Clinically intermediate between trait and major; patients maintain baseline Hb levels between 7.0 and 10.0 g/dL.

Exhibit moderate splenomegaly, bone changes, and iron overload (from hyperabsorption driven by suppressed hepcidin), but remain transfusion-independent under baseline conditions.

3. Beta Thalassemia Major (Cooley Anemia: Homozygous β 0 / β 0 \beta^0/\beta^0 β 0 / β 0 or Severe β + / β + \beta^+/\beta^+ β + / β + )

Clinical Onset : Becomes clinically apparent between 6 and 9 months of age , as physiological fetal γ \gamma γ -to- β \beta β globin chain switching occurs and Hb F production declines.

Pathophysiology : Severe absence of β \beta β -chains leaves massive excess of free α \alpha α -chains, causing catastrophic ineffective erythropoiesis, profound anemia (Hb 3–6 g/dL), severe hepatosplenomegaly, and endocrine failure.

Lifelong Management : Requires lifelong regular erythrocyte transfusions (every 2–4 weeks) paired with iron chelation therapy (deferoxamine, deferasirox) to prevent fatal secondary hemochromatosis (cardiac failure, hepatic cirrhosis).

Peripheral Smear Morphology : Severe anisopoikilocytosis, microcytic hypochromic "ghost-like" cells, abundant target cells (codocytes), teardrop cells (dacrocytes), marked basophilic stippling, and a dramatic shower of nucleated red blood cells (NRBCs: 20–100+ per 100 WBCs) .

Electrophoresis / HPLC : Hemoglobin F > 90% , variable Hb A 2 A_2 A 2 ​ , and completely absent Hb A (in β 0 / β 0 \beta^0/\beta^0 β 0 / β 0 ) or trace Hb A (in β + / β + \beta^+/\beta^+ β + / β + ).

Delta-Beta Thalassemia & Hereditary Persistence of Fetal Hemoglobin (HPFH)

δ β \delta\beta δ β -Thalassemia : Deletion of both adjacent δ \delta δ and β \beta β genes on chromosome 11. Homozygotes produce 100% Hb F with mild microcytic hypochromic anemia; heterozygotes produce 5–20% Hb F with normal or decreased Hb A 2 A_2 A 2 ​ .

Hereditary Persistence of Fetal Hemoglobin (HPFH) : Genetic deletion or promoter point mutations that prevent the normal developmental silencing of γ \gamma γ -globin gene expression in adulthood. Homozygotes have 100% Hb F with completely normal red cell lifespan, normal indices, and no anemia because γ \gamma γ -chains fully compensate for β \beta β -chains.

Intracellular Distribution of Hb F :

Pancellular (Homogeneous) : Hb F is distributed uniformly across 100% of erythrocytes (classic for HPFH ).

Heterocellular (Heterogeneous) : Hb F is distributed unevenly among a subpopulation of red blood cells ("F-cells") (classic for δ β \delta\beta δ β -thalassemia, β \beta β -thalassemia , and Sickle Cell Anemia).

The Kleihauer-Betke Acid Elution Test Kleihauer-Betke Acid Elution Principle

  • [Blood Smear Fixed in 80% Ethanol] ──► [Incubated in Citrate Buffer (pH 3.2 - 3.3)]
  • │
  • ┌───────────────────────────────────┴───────────────────────────────────┐
  • ▼ ▼
  • [Adult Hemoglobin (Hb A)] [Fetal Hemoglobin (Hb F)]
  • Acid-SOLUBLE • Acid-RESISTANT
  • Elutes completely from erythrocytes • Remains precipitated inside cells
  • Appears as colorless 'Ghost Cells' • Stains DEEP PINK with Eosin/Erythrosin
  • Principle and Methodology

The Kleihauer-Betke (KB) test is a quantitative acid elution slide assay used to differentiate and count fetal red blood cells in maternal circulation:

A peripheral blood smear is prepared, fixed in 80% ethanol, and immersed in an acid buffer (citric acid-phosphate, pH 3.2–3.3) at 37°C.

Adult hemoglobin (Hb A) is acid-soluble; it rapidly dissolves and elutes out of maternal erythrocytes into the buffer, leaving empty, colorless, translucent cell membranes ( "ghost cells" or stroma).

Fetal hemoglobin (Hb F) is structurally resistant to acid elution; it remains precipitated inside fetal erythrocytes.

The smear is counterstained with erythrosin B or eosin. Under microscopic evaluation, fetal cells stain dark, bright pink/red , while maternal cells appear as pale, unstained ghost outlines .

Clinical Application: Fetomaternal Hemorrhage (FMH) & RhIG Dosing

The KB test quantifies the volume of fetomaternal hemorrhage (FMH) in Rh-negative mothers who give birth to Rh-positive infants, determining the required dose of Rh Immune Globulin (RhIG / RhoGAM) : Fetal Cells (%) = Number of Pink Fetal Cells Total Cells Counted (2,000) × 100 \text{Fetal Cells (\%)} = \frac{\text{Number of Pink Fetal Cells}}{\text{Total Cells Counted (2,000)}} \times 100 Fetal Cells (%) = Total Cells Counted (2,000) Number of Pink Fetal Cells ​ × 100 Fetal Whole Blood (mL) = Fetal Cells (%) × 50 \text{Fetal Whole Blood (mL)} = \text{Fetal Cells (\%)} \times 50 Fetal Whole Blood (mL) = Fetal Cells (%) × 50 Vials of RhIG (300 μ g) = Fetal Whole Blood (mL) 30 + 1 (Safety Buffer) \text{Vials of RhIG (300 }\mu\text{g)} = \frac{\text{Fetal Whole Blood (mL)}}{30} + 1\text{ (Safety Buffer)} Vials of RhIG (300 μ g) = 30 Fetal Whole Blood (mL) ​ + 1 (Safety Buffer)

Rounding Rule : When calculating the number of vials, divide the fetal whole blood volume by 30. If the decimal is ≥ 0.5 \ge 0.5 ≥ 0.5 , round up to the next whole number and add 1 vial. If the decimal is < 0.5 < 0.5 < 0.5 , round down to the whole number and add 1 vial.

Comprehensive Thalassemia Syndromes Reference Matrix

Syndrome Globin Genotype Clinical Severity MCV (fL) RBC Count ( 10 12 10^{12} 1 0 12 /L) Hemoglobin Electrophoresis / HPLC Special Diagnostic Features

α \alpha α -Thal Silent Carrier − α / α α -\alpha/\alpha\alpha − α / αα Asymptomatic 78–82 Normal Adult: Normal; Cord blood: 1–2% Barts DNA gene deletion analysis

α \alpha α -Thal Trait / Minor − α / − α -\alpha/-\alpha − α / − α or − − / α α --/\alpha\alpha − − / αα Mild microcytosis, no anemia 65–75 High ( > 5.0 – 6.0 >5.0–6.0 > 5.0–6.0 ) Adult: Normal; Cord blood: 5–10% Barts Mentzer Index < 13; normal Hb A 2 A_2 A 2 ​

Hemoglobin H Disease − − / − α --/-\alpha − − / − α Moderate hemolytic anemia, splenomegaly 55–65 Normal to High Hb H: 5–30% (fast anodal band), decreased Hb A 2 A_2 A 2 ​ "Golf ball" inclusions on BCB supravital stain

Hb Barts Hydrops Fetalis − − / − − --/-- − − / − − Fatal in utero (Hydrops) <60 Marked Anemia Hb Barts: 80–90% , trace Hb Portland, 0% Hb A Complete absence of α \alpha α -chains; lethal

β \beta β -Thal Minor / Trait β + / β \beta^+/\beta β + / β or β 0 / β \beta^0/\beta β 0 / β Mild microcytic anemia (Hb 10–13) 58–70 Strikingly High ( > 5.0 – 6.5 >5.0–6.5 > 5.0–6.5 ) Elevated Hb A 2 A_2 A 2 ​ (3.5–7.0%) , Hb F 1–3% Mentzer Index < 13; basophilic stippling

β \beta β -Thal Major (Cooley) β 0 / β 0 \beta^0/\beta^0 β 0 / β 0 Severe transfusion-dependent anemia <65 Critically Low Hb F > 90% , absent/trace Hb A Shower of NRBCs, extreme target cells, iron overload

HPFH (Heterozygote) ( δ β ) 0 / β (\delta\beta)^0/\beta ( δ β ) 0 / β (HPFH) Asymptomatic, no anemia Normal Normal Hb F: 15–30% , normal Hb A 2 A_2 A 2 ​ Pancellular (homogeneous) Hb F distribution